Barron's market reporter Jacob Sonenshine breaks down the market as the Fed meeting kicks off and spotlights pharmaceutical company Merck.

While economic data may be scarce, every data point gives a new angle to the ever-uncertain economic conditions in the US.

Daniel Robinson is a writer based in Greenville, N.C. with expertise in auto insurance, loans, warranty options and more. Away from the keyboard, Daniel spends time with his wife and son, plays ...

Learn more. If you're shopping for the best car covers to protect your vehicle's paint while it's parked, you've come to the right place. Not everyone has the luxury of parking their car in a ...

We earn commissions from purchases you make using links in our articles. Learn more. Here are the best car waxes you can buy that will give you great results and help protect your paint.

Based in Boston, Marcos Cabello is a personal finance reporter for NextAdvisor and CNET. Marcos has covered cryptocurrency, investing, banking, and the US economy, among other personal finance ...

Merck’s cancer immunotherapy Keytruda is the drug industry’s biggest blockbuster, bringing in $25 billion in sales last year. For years drug companies have sought to beat the therapy to no avail.

However, a handful of vehicles consistently outshine the rest, securing their positions as the top-selling cars in India. The competition in the Indian automobile industry is fierce, and in 2023 ...

Forza Horizon 5 takes car lovers and fanatics on a road trip across Mexico, spanning harsh deserts and lush rainforests. Playground Games has delivered its most ambitious and advanced entry yet ...

Sacituzumab tirumotecan is under clinical development by Merck and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II drugs for Endometrial Cancer have a 22% phase ...

AbbVie is a Dividend King with solid growth prospects. Merck's looming patent cliff isn't as alarming as it might seem. Pfizer offers a high dividend yield and lots of upside potential.